About DIMA BIOTECH
DIMA Biotechnology provides preclinical R&D solutions for BioPharma, offering 5000+ validated mAbs and 300+ full-length multipass transmembrane proteins. Our platforms include Nanodisc, single B-cell mAb discovery, and mammalian cell display for antibody engineering – advancing drug development across GPCRs, ion channels, and other high-value difficult drug targets.
What We Showcase at AACR
01 DiMProTM Nanodisc Membrane Protein Platforms
- Full-length GPCR proteins in native conformation
- Ion channel and multi-pass membrane protein solutions
- Stable and functional protein formats for drug discovery
- 700+ Nanodisc proteins, with 300+ in stock
02 Ready-to-Test Lead mAbs for Therapeutic Targets
-
5000+ Pre-validated IgG Sequences with Global Licensing Options, 500+ Druggable Targets
-
Zero Upfront, Zero Waiting, Zero Risk
- Immediate Testing (Pre-clinical Validation Data PackageAvailable)
- Functional Evaluation Data on Different ModalityPlatforms (CAR-T, ADC, BsAb, etc.)
- Mammalian Cell Display Based Antibody Engineering Platform for lead mAbs Optimization(Humanization, Affinity Maturation, PTM Risk Removal)
Visit DIMA BIOTECH at AACR 2026
We welcome you to visit our booth (Booth #1704) for live discussions, product insights, and collaboration opportunities.
Resources
DIMA BIOTECH Highlights
Nanodiscs
ADC-Reagents
Schedule a Meeting with Our Team
Secure a one-on-one meeting with our scientists and technical experts at AACR 2026.
Please share your details below: